PSYBF (PsyBio Therapeutics) Shares Outstanding (EOP): 127.54 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics Shares Outstanding (EOP)?

PsyBio Therapeutics PSYBF -90.00% Shares Outstanding (EOP) is 127.54 Mil as of Jun. 2023.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. PsyBio Therapeutics's shares outstanding for the quarter that ended in Jun. 2023 was 127.54 Mil.

PsyBio Therapeutics's quarterly shares outstanding declined from Mar. 2023 (129.54 Mil) to Jun. 2023 (127.54 Mil). It means PsyBio Therapeutics bought back shares from Mar. 2023 to Jun. 2023 .

PsyBio Therapeutics's annual shares outstanding declined from Dec. 2021 (112.96 Mil) to Dec. 2022 (111.34 Mil). It means PsyBio Therapeutics bought back shares from Dec. 2021 to Dec. 2022 .


PsyBio Therapeutics  (OTCPK:PSYBF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


PsyBio Therapeutics Shares Outstanding (EOP) Related Terms


PsyBio Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics Shares Outstanding (EOP) Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
Shares Outstanding (EOP)
112.96 111.34

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.34 111.34 111.34 129.54 127.54

PSYBF vs VRTX, REGN, SGEN: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, PsyBio Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PsyBio Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's Shares Outstanding (EOP) falls into.



PsyBio Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 127.54 Mil mean?
PsyBio Therapeutics (PSYBF) has a Shares Outstanding (EOP) of 127.54 Mil as of Jun. 2023. The total shares a company has outstanding, at period-end. View historical data on PsyBio Therapeutics and its competitors.
Is PsyBio Therapeutics' Shares Outstanding (EOP) too high?
PsyBio Therapeutics' current Shares Outstanding (EOP) is 127.54 Mil.
How does PsyBio Therapeutics' Shares Outstanding (EOP) compare to VRTX and REGN?
PsyBio Therapeutics' Shares Outstanding (EOP) of 127.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on PsyBio Therapeutics and its competitors. PsyBio Therapeutics's current Shares Outstanding (EOP) is 127.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (PSYBF) has a current Shares Outstanding (EOP) of 127.54 Mil. The current Shares Outstanding (EOP) is 127.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For PsyBio Therapeutics (PSYBF), the current Shares Outstanding (EOP) is 127.54 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.